Non-Hodgkin's Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials

A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma
Conditions:   Advanced Solid Tumors;   Relapsed/Refractory Non-Hodgkin Lymphoma;   Relapsed/Refractory Multiple Myeloma Intervention:   Biological: GIC-102 (Allogeneic NK cells) Sponsor:   GI Cell, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Conditions:   NHL;   NHL, Relapsed, Adult Intervention:   Drug: CLN-978 Sponsor:   Cullinan Oncology, LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials

A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma
Conditions:   Advanced Solid Tumors;   Relapsed/Refractory Non-Hodgkin Lymphoma;   Relapsed/Refractory Multiple Myeloma Intervention:   Biological: GIC-102 (Allogeneic NK cells) Sponsor:   GI Cell, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Conditions:   NHL;   NHL, Relapsed, Adult Intervention:   Drug: CLN-978 Sponsor:   Cullinan Oncology, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma
Conditions:   Advanced Solid Tumors;   Relapsed/Refractory Non-Hodgkin Lymphoma;   Relapsed/Refractory Multiple Myeloma Intervention:   Biological: GIC-102 (Allogeneic NK cells) Sponsor:   GI Cell, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Conditions:   NHL;   NHL, Relapsed, Adult Intervention:   Drug: CLN-978 Sponsor:   Cullinan Oncology, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Condition:   Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Intervention:   Drug: SC291 Sponsor:   Sana Biotechnology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2023 Category: Research Source Type: clinical trials

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Conditions:   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Transformed Chronic Lymphocytic Leukemia;   Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma;   Recurrent Transformed B-Cell Non-Hodgkin Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Interventions:   Procedure: Biospecimen Collection;   Procedure: Bone Marrow Biopsy;   Procedure: Computed Tomography;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Proce...
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials